There is decreased risk for MACE and all-cause mortality in dialysis-dependent patients with ASCVD who are treated with statins.

The FDA has approved a labeling update for Leqvio (inclisiran) allowing for first-line use in the treatment of hypercholesterolemia.

Recent studies may challenge the thinking about lipoprotein(a) as a risk factor for cardiovascular events, but experts say ...

Objective Functional complete revascularisation (FCR) has been proven to be associated with superior prognosis following ...

Ultragenyx Pharmaceutical RARE reported second-quarter 2025 loss of $1.17 per share, narrower than the Zacks Consensus ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biotechnology company focused on improving patient outcomes through ...

Extending cardiovascular disease prevention beyond health care settings is needed to improve population health and to advance health equity. Furthermore, evidence-based practices in community settings ...

Ozempic has become a popular off-label tool to support weight management. Learn what experts say on Ozempic for weight loss, its safety and effectiveness.